Children's Hospital of Philadelphia leads or participates in hundreds of clinical trials. Use this database to learn the purpose of these trials, find out who can participate and more.
11 - 20 of 124
The Lurie Family Foundations MEG Imaging Lab at CHOP are looking for Healthy Children for a study on how the brain works. We are looking for both male and female children between the ages of 8-12 years old. We will provide you with reimbursement for your time and parking will be at no cost. For more information please contact our study coordinator Leah Gaetz at 267-426-4914 or firstname.lastname@example.org. IRB 16-012890
Collect data and blood samples to make observations and determinations about rate and severity of graft-versus-host disease in HCT patients. IRB 16-012909
Our team is trying to understand how wearing the Boston (TLSO) brace can affect three-dimensional (3D) changes in the spine and ribcage. We are looking to partner with families who have an adolescent who will be treated with a brace and is between the age of 10 and 16 years. Our study is observational, which means that your child will NOT be asked to make any changes to their daily life. If your child agrees to participate, he or she will be asked to wear a smart strap, a strap that replaces one of the regular straps on the brace. The smart strap will be free of charge and registers brace wear duration and strap tension via Bluetooth, therefore patients and families can track treatment information and see their prescription through a smartphone app. IRB 16-013059
Concussion is a highly prevalent condition in adolescence, but it remains a clinical diagnosis that largely relies on subjective patient symptom-report as there are currently no reliable objective biomarkers for diagnosis. This study will ask adolescents with and without a concussion to undergo neuroimaging and neuropsychological testing to better understand the biological basis of brain pathology and to assess the predictive value of the brain imaging biomarkers with respect to clinical outcomes in adolescents with concussion. IRB 16-013207
The purpose of this study is to identify and engage young black or hispanic/latino men (male sex at birth, but gender identity male, transfemale, or gender nonconforming) in Philadelphia, PA, Baltimore, MD and Washington, DC in HIV and substance use prevention using a new Mobile-enhanced Engagement intervention (app that reminds you to take your meds, reminds you of your medical appointments, etc.). There are three different parts to this study: 1) respondent driven sampling (RDS); 2) Randomized Control Trial (RCT): MEI vs Standard of Care for HIV+ youth; and 3) PrEP RCT: Pre Exposure Prophylaxis - Mobile-enhanced Engagement Intervention (PrEP-MEI) vs. Standard PrEP referral;. It is possible to participate in only the RDS, the RDS and the AIM 3 PrEP RCT, or the RDS and AIM 2 RCT studies.
The RDS study involves 2 study visits lasting up to 1 month of participation where participants will be asked to complete a rapid oral HIV test, web-based survey (on past sexual and HIV experiences), recruit your peers to participate in the study, and complete a post-recruitment survey.
The RCT study involves 6 study visits (5 in person, 1 phone) and lasts 18 months. Participants will be assigned to one of two groups receiving different HIV supportive interventions: 1) HIV case management with a Mobile-enhanced Engagement Intervention (MEI), or 2) standard of care HIV case management where a case manager will remind you of medical appointments. If you are assigned to the first group (MEI), you will be asked to use the MEI mobile app or web-browser version of the app during the study period. Participants will be asked to complete a web-survey (on past sexual and HIV experiences), HIV Antibody and Viral load testing (blood draw), urine drug testing, and allow the researchers to access your medical charts for HIV and STI testing results. You may also be asked to participate in audio-recorded in-depth interviews.
The PrEP RCT study involves 5 study visits (4 in person, 1 phone) and lasts 12 months. Participants will be assigned to one of two groups receiving different PrEP and substance use supportive interventions: 1) PrEP case management with a Mobile-enhanced Engagement Intervention (MEI-PrEP), or 2) standard PrEP referrals to services. If you are assigned to the first group (MEI-PrEP), you will be asked to use the MEI-PrEP mobile app or web-browser version of the app during the study period. Participants will be asked to complete a web-survey (on past sexual and HIV experiences), HIV Antibody and Viral load testing (blood draw), urine drug testing, use the MEI-PrEP mobile app or web-browser version of the app, and allow the researchers to access your medical charts for HIV and STI testing results. You may also be asked to participate in audio-recorded in-depth interviews. IRB 16-013396
Patients with no available curative treatment options with leukemia are eligible to participate in this study to test an experimental approach called gene transfer that involves B cells. This study will take the patients white blood cells - T cells - and change them to turn against the cancer. IRB 16-013488
We are conducting a research study on the genetics of PHACE Syndrome. The purpose of this study is to develop a better understanding of the cause of PHACE Syndrome by collecting DNA in the forms of cells from skin biopsies, tissue specimens, blood samples, and/or buccal swabs. Individuals (any age) or family members of patients with PHACE Syndrome or a large segmental hemangioma can participate. What we learn from this study will help us to provide individuals with PHACE syndrome and their relatives more detailed and accurate information about the etiology of the disease. IRB 16-013503
This is a clinical trial to study the use of Tadekinig alfa or placebo (medication) in the treatment of NLRC4 MAS mutation or XIAP deficiency. This study involves taking the medication every 48 hours for up to 26 weeks. Participants will also be required to attend up to 14 in-person study visits to review their disease state while they are taking the medication. Compensation for time and travel related to study visits may be provided to qualified participants. IRB 17-013986
Researchers want to find out if bardoxolone methyl, a drug being developed by Reata Pharmaceuticals, can improve Alport Syndrome, with its disease-modifying effects in kidney function. Bardoxolone methyl is an investigational (experimental) drug that is being tested, and is not currently approved by the U.S. Food and Drug Administration (FDA), or any other regulatory agency for sale in the United States or any other country. In this study, bardoxolone methyl will be given to approximately 210 patients with Alport Syndrome from approximately 60 study centers who are between the ages of 12 and 60. The trial will consist of two cohorts (i.e. groups). Cohort 1 is considered a Phase 2 study, and will enroll up to 30 subjects. Cohort 1 will be open-label where everyone involved in the study (including you) know that the study drug being used will ONLY be bardoxolone methyl capsules. CHOP will not be participating in Cohort 1.
Cohort 2 will be a double-blind, randomized, placebo-controlled, Phase 3 study, and will enroll up to 180 subjects. This means that you will be randomly assigned (like flipping a coin) to either bardoxolone methyl, or a placebo (i.e. inactive substance/sugar pill), and that both you AND your doctor will not know which drug you are assigned to. IRB 17-013989
The Center for Autism Research is looking for teens and adults ages 12 and older with autism spectrum disorder to participate in a research study testing the effectiveness of a new virtual reality (VR) application aimed at improving social skills. Participation in this study involves one to three visits to CAR to use the VR headset and complete questionnaires. Participants will be compensated for their time. IRB 17-014194